This week, ASCRS and 239 members of the medical community, including medical societies, patient advocacy groups, and life science organizations, sent a letter to Senate and House leadership asking them to urge the Centers for Medicare & Medicaid Services (CMS) to reconsider allowing Medicare Advantage (MA) plans to implement step therapy programs for Medicare Part B drugs. Beginning in January 2019, MA plans could require patients to try and fail certain treatments before allowing access to other, potentially more appropriate treatments. ASCRS and the medical community are concerned that implementing step therapy in MA plans will harm patients and undermine clinical decision making. This is the third letter ASCRS has signed on to in the last two weeks urging CMS to withdraw this new policy. We will keep you updated.